Literature DB >> 23430441

Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma.

Haiqing Cai1, Lijun Lin, Haikang Cai, Mingjie Tang, Zhigang Wang.   

Abstract

MicroRNA-210 (miR-210) plays important roles in the regulation of cell growth, angiogenesis, and apoptosis in different cancer type. Previous study of miRNA expression profiling found that miR-210 was significantly elevated in osteosarcoma samples. However, its roles in this disease have not been fully elucidated. Thus, the aim of this study was to investigate the association of miR-210 expression with clinicopathologic features and prognosis in patients with osteosarcomas. Quantitative real-time reverse transcriptase-polymerase chain reaction analysis was performed to detect the expression level of miR-210 in cancerous and noncancerous bone tissues from 92 children treated for primary osteosarcomas. MiR-210 expression was significantly increased in osteosarcoma tissues compared with that in corresponding noncancerous bone tissues (P < 0.001). In addition, miR-210 upregulation more frequently occurred in osteosarcoma tissues with large tumor size (P = 0.02), poor response to preoperative chemotherapy (P = 0.008), and positive metastasis (P = 0.01). Moreover, miR-210 upregulation was associated with significantly decreased overall survival (P = 0.007) and progression-free survival (P = 0.01). In the Cox proportional hazard model, it was confirmed that its expression in the biopsy samples was an independent prognostic factor of unfavorable survival in osteosarcoma (for overall survival: P = 0.01; for progression-free survival: P = 0.02). These findings suggested that miR-210 upregulation showed a strong correlation with tumor aggressive progression of pediatric osteosarcoma and could help prognostic screening of patients with this malignancy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23430441     DOI: 10.1007/s12032-013-0499-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  An integrated approach for experimental target identification of hypoxia-induced miR-210.

Authors:  Pasquale Fasanaro; Simona Greco; Maria Lorenzi; Mario Pescatori; Maura Brioschi; Ritu Kulshreshtha; Cristina Banfi; Andrew Stubbs; George A Calin; Mircea Ivan; Maurizio C Capogrossi; Fabio Martelli
Journal:  J Biol Chem       Date:  2009-10-13       Impact factor: 5.157

Review 2.  The epidemiology of osteosarcoma.

Authors:  Giulia Ottaviani; Norman Jaffe
Journal:  Cancer Treat Res       Date:  2009

3.  Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients.

Authors:  T Greither; P Würl; L Grochola; G Bond; M Bache; M Kappler; C Lautenschläger; H-J Holzhausen; S Wach; A W Eckert; H Taubert
Journal:  Int J Cancer       Date:  2011-06-21       Impact factor: 7.396

4.  High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis.

Authors:  Liu Hong; Jianjun Yang; Yu Han; Qun Lu; Jun Cao; Labiq Syed
Journal:  Gene       Date:  2012-07-25       Impact factor: 3.688

5.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

Review 6.  MicroRNA-mediated gene regulations in human sarcomas.

Authors:  Subbaya Subramanian; Reena V Kartha
Journal:  Cell Mol Life Sci       Date:  2012-08-25       Impact factor: 9.261

7.  The molecular pathogenesis of osteosarcoma: a review.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Damian E Myers; Crispin R Dass; Peter F M Choong
Journal:  Sarcoma       Date:  2011-04-13

Review 8.  Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.

Authors:  J PosthumaDeBoer; M A Witlox; G J L Kaspers; B J van Royen
Journal:  Clin Exp Metastasis       Date:  2011-04-02       Impact factor: 5.150

9.  Identification of Differentially Expressed MicroRNAs in Osteosarcoma.

Authors:  Rishi R Lulla; Fabricio F Costa; Jared M Bischof; Pauline M Chou; Maria de F Bonaldo; Elio F Vanin; Marcelo B Soares
Journal:  Sarcoma       Date:  2011-07-18

10.  Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers.

Authors:  Jen-Tsan Chi; Zhen Wang; Dimitry S A Nuyten; Edwin H Rodriguez; Marci E Schaner; Ali Salim; Yun Wang; Gunnar B Kristensen; Aslaug Helland; Anne-Lise Børresen-Dale; Amato Giaccia; Michael T Longaker; Trevor Hastie; George P Yang; Marc J van de Vijver; Patrick O Brown
Journal:  PLoS Med       Date:  2006-03       Impact factor: 11.069

View more
  27 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  MicroRNA-150 upregulation reduces osteosarcoma cell invasion and metastasis by downregulating Ezrin.

Authors:  Ce Zhan; Cheng Li; Hao Zhang; Hao Tang; Fang Ji; Su-Chi Qiao; Wei-Dong Xu; Zhi-Wei Wang
Journal:  Oncol Lett       Date:  2016-08-25       Impact factor: 2.967

Review 3.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

4.  Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma.

Authors:  Jie Yang; Tiantian Gao; Jie Tang; Haikang Cai; Lijun Lin; Shiping Fu
Journal:  Mol Cell Biochem       Date:  2013-06-26       Impact factor: 3.396

Review 5.  HypoxamiRs and cancer: from biology to targeted therapy.

Authors:  Harriet E Gee; Cristina Ivan; George A Calin; Mircea Ivan
Journal:  Antioxid Redox Signal       Date:  2013-11-22       Impact factor: 8.401

6.  Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma.

Authors:  Scott M Riester; Jorge Torres-Mora; Amel Dudakovic; Emily T Camilleri; Wei Wang; Fuhua Xu; Roman R Thaler; Jared M Evans; René Zwartbol; Inge H Briaire-de Bruijn; Avudaiappan Maran; Andrew L Folpe; Carrie Y Inwards; Peter S Rose; Thomas C Shives; Michael J Yaszemski; Franklin H Sim; David R Deyle; Annalise N Larson; Mario A Galindo; Arjen G H Cleven; Andre M Oliveira; Anne-Marie Cleton-Jansen; Judith V M G Bovée; Andre J van Wijnen
Journal:  J Orthop Res       Date:  2016-06-28       Impact factor: 3.494

Review 7.  Review of microRNA in osteosarcoma and chondrosarcoma.

Authors:  Le Chang; Swati Shrestha; Greg LaChaud; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-04-26       Impact factor: 3.064

8.  Prognostic role of microRNA-210 in various carcinomas: a meta-analysis.

Authors:  Xuejiao Xie; Wenhong Wu; Ludong Liang; Shuai Han; Ting Chen; Shangling Pan; Meijuan Xue; Shikang Li
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 9.  MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects.

Authors:  Jinglei Miao; Song Wu; Zhi Peng; Mousumi Tania; Chaoyue Zhang
Journal:  Tumour Biol       Date:  2013-08

10.  The expression and function of miRNA-451 in osteosarcoma.

Authors:  Jiandong Yuan; Junzhe Lang; Cailong Liu; Kai Zhou; Lei Chen; Yangbo Liu
Journal:  Med Oncol       Date:  2014-12-04       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.